Brian I. Rini, MD, discusses atezolizumab plus bevacizumab as an effective frontline combination in renal cell carcinoma, as well as patient reported outcomes with the regimen.
Original Article: Expert Highlights Atezolizumab/Bevacizumab Combo in RCC